DINGYI GP INV(00508): Kaiyuan Xinde resigned as the company's auditor.
Dingyi Group Investment (00508) announced that the board of directors and the company's audit committee have received the auditor's report from Ernst & Young.
DINGYI GP INV (00508) announced that the Board of Directors and Audit Committee have received a letter from Horwath HK CPA Limited dated September 24, 2024, indicating that they will retire as the company's auditors after the current term ends. They will not seek reappointment as the company's auditors at the shareholders' annual meeting to be held at 3:00 p.m. on September 26, 2024.
Related Articles
Yahong Pharmaceutical (688176.SH): APL-2401 clinical trial application approved by the National Medical Products Administration.
Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.
New Stock News | Hua Rong Bio-B (02396) IPO ends, with a subscription amount of HK$53.6 billion, oversubscribed 594 times.
Yahong Pharmaceutical (688176.SH): APL-2401 clinical trial application approved by the National Medical Products Administration.
Yabao Pharmaceutical Group (600351.SH): GLX002 has obtained the notice of approval for clinical trial of the drug.
New Stock News | Hua Rong Bio-B (02396) IPO ends, with a subscription amount of HK$53.6 billion, oversubscribed 594 times.
RECOMMEND
Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025
What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025
Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025
